Panbela Therapeutics
@panbela.com
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for urgent unmet medical needs. The objective of Panbela’s pipeline is the utilization of pharmacotherapies to reduce/normalize increased disease-associated polyamines using complementary pharmacotherapies.
Panbela Therapeutics's Company Logos
Panbela Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#413B90
Gigas
65, 59, 144
244, 42, 40
55, 59, 0, 44
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#383838
Mine Shaft
56, 56, 56
0, 0, 22
0, 0, 0, 78
About Panbela Therapeutics
Panbela Therapeutics is a clinical-stage biopharmaceutical company that is dedicated to developing groundbreaking therapeutics to address urgent and unmet medical needs. The focus of their pipeline is on utilizing pharmacotherapies to reduce and normalize disease-associated polyamines, using a combination of complementary treatments. Their lead assets include ivospemin (SBP-101) and CPP-1X, which can be utilized alone or in conjunction with Sulindac (Flynpovi™).
These assets provide a multi-targeted approach to reset dysregulated biology found in various diseases, including cancer and autoimmunity. By targeting the polyamine pathway at different points, these assets have the potential to suppress tumor growth, enhance the effectiveness of other anti-cancer treatments, and modulate the immune system. Panbela's development program covers a wide range, from pre-clinical to registration programs.
Their late-stage programs focus on ivospemin (SBP-101) for first-line metastatic pancreatic cancer and Flynpovi™ for familial adenomatous polyposis (FAP). With a commitment to scientific innovation and medical advancement, Panbela Therapeutics is at the forefront of revolutionizing healthcare and improving patient outcomes
